Effect of tiered prescription copayments on the use of preferred brand medications.
about
Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data.Systematic review on quality control for drug management programs: is quality reported in the literature?Trends in pharmaceutical expenditures: the impact on drug benefit designPharmaceutical cost management and access to psychotropic drugs: the U.S. contextImpact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.How do quality information and cost affect patient choice of provider in a tiered network setting? Results from a survey.Employer-paid nonmedical costs for patients with diabetes and end-stage renal disease.ENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'SHow patient cost-sharing trends affect adherence and outcomes: a literature review.Pharmacy utilization and the Medicare Modernization Act.Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication useThe effect of three-tier formulary adoption on medication continuation and spending among elderly retirees.What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries.Impact of multitiered copayments on the use and cost of prescription drugs among Medicare beneficiaries.Using the deductible for patient channeling: did preferred providers gain patient volume?The introduction of generic risperidone in Medicare Part DEffects of a consumer driven health plan on pharmaceutical spending and utilization.Is there a relationship between patient beliefs or communication about generic drugs and medication utilization?Drug licenses: a new model for pharmaceutical pricingWhat is in your wallet? A cluster randomized trial of the effects of showing comparative patient out-of-pocket costs on primary care prescribing for uncomplicated hypertension.An evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011-2016): an interrupted time-series study.
P2860
Q33404862-A42590A9-DBE5-4D40-B471-8EADFBD6145DQ33412577-ADE56019-CBF9-4DD8-8D3C-5AF4CEBE2D41Q33932532-DCDF6C9E-73B2-4514-97F6-03B7C0D8851AQ34390982-B64107DB-BBC6-4DEB-BEF9-CE67C462367AQ34452710-571B19BA-D812-47E6-84D6-0F66C0D2B4D2Q34724735-15463F93-66C1-450C-ADA0-EAD7AE7B96C6Q35131284-FF325108-208E-49C2-9648-4645EE092109Q35215867-69D9A166-1D47-4E50-9F30-1CBB9B64B00AQ35752951-32F78172-4D13-4B47-AAC5-D9F2C4C54CB4Q36078786-BF6590A7-68CF-47B1-87E2-5BBF77550D28Q36416773-E64970A2-0B34-471F-9042-5B838758F087Q36478520-215E0B54-AD5A-42CA-894D-CD8097AE75F9Q36699426-F352BDCB-99EE-4F45-8C76-BD5F526D8EB4Q36741644-E8EBC5D2-DE41-4243-B351-15E5ED012768Q36903469-83EE33C7-FB4E-4C11-A8A3-87295B42878AQ37024443-81AD08AC-8CDF-492A-845B-6A3314600B0BQ37123672-3F24AC76-BEDC-46A7-9752-59FCF3E3F315Q37246833-841B6698-05E2-449A-AB15-A172DABE7167Q42576240-8A6DE8F4-39D6-41B9-AA00-20E90E623D00Q47565817-24EC068C-D1D9-4C77-8210-52BC0A218D91Q55361793-0506D544-6A3E-4D2F-89D0-01FCE922B354
P2860
Effect of tiered prescription copayments on the use of preferred brand medications.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Effect of tiered prescription copayments on the use of preferred brand medications.
@ast
Effect of tiered prescription copayments on the use of preferred brand medications.
@en
type
label
Effect of tiered prescription copayments on the use of preferred brand medications.
@ast
Effect of tiered prescription copayments on the use of preferred brand medications.
@en
prefLabel
Effect of tiered prescription copayments on the use of preferred brand medications.
@ast
Effect of tiered prescription copayments on the use of preferred brand medications.
@en
P2093
P1433
P1476
Effect of tiered prescription copayments on the use of preferred brand medications.
@en
P2093
Bharati S Manda
Mark V Pauly
Michael D Finch
Patricia M Danzon
Thomas S Rector
P304
P356
10.1097/00005650-200303000-00008
P577
2003-03-01T00:00:00Z